+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Theranostics Market - Global Forecast to 2030- Product Image
Theranostics Market - Global Forecast to 2030- Product Image
New

Theranostics Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083045
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Theranostics Market grew from USD 2.67 billion in 2024 to USD 3.09 billion in 2025. It is expected to continue growing at a CAGR of 15.03%, reaching USD 6.19 billion by 2030.

Theranostics represents the convergence of diagnostic imaging and targeted therapy, ushering in an era where personalized treatment plans are guided by real-time molecular insights. Over the past decade, this approach has transformed oncology by enabling more precise tumor detection, monitoring therapeutic response and minimizing off-target effects. Emerging modalities such as radiopharmaceuticals and nanoparticle-based probes have broadened the scope of applications beyond cancer, reaching into cardiology, neurology and infectious diseases. Innovations in biomarker discovery and imaging technology, coupled with advances in antibody engineering and peptide synthesis, have accelerated the translation of theranostic research from bench to bedside.

As regulatory agencies adapt frameworks to accommodate complex modalities, stakeholders are navigating new pathways for approval and reimbursement. Strategic partnerships between pharmaceutical developers, diagnostic laboratories and academic institutions are critical to overcoming manufacturing challenges and ensuring consistent supply chains. In this dynamic environment, decision-makers require a cohesive synthesis of market drivers, technological breakthroughs and competitive positioning to chart a sustainable growth trajectory.

Transformative Shifts Redefining Theranostics Applications

Theranostics is undergoing transformative shifts driven by the integration of precision medicine and advanced imaging. The rise of radiopharmaceutical innovations-leveraging monoclonal antibodies, peptides and nanoparticles conjugated with diagnostic isotopes-has enhanced sensitivity and specificity for detecting malignancies. Concurrently, fluorescence-guided surgery using fluorescent proteins is gaining traction to delineate tumor margins in real time.

Artificial intelligence and machine learning are accelerating biomarker discovery by analyzing vast datasets from genomic, proteomic and imaging sources, thereby streamlining candidate validation and patient stratification. Regulatory bodies are revising guidance to address combined diagnostics and therapeutics, facilitating expedited approval pathways. Moreover, the adoption of modular manufacturing platforms for radiopharmaceuticals is reducing lead times and enhancing scalability. These shifts are fostering a more agile ecosystem, enabling quicker translation of novel agents into clinical practice and reinforcing the role of theranostics as a cornerstone of personalized care.

Cumulative Impact of United States Tariffs in 2025

The implementation of new United States tariffs in 2025 has imposed additional duties on imported components and isotopes critical to theranostic development. This policy change has elevated production costs, prompting stakeholders to reassess supply chain strategies. Companies are exploring domestic synthesis of radiopharmaceutical precursors to mitigate exposure to duty fluctuations, while parallel negotiations are underway to secure exemptions for key raw materials.

As a result, collaborative frameworks between commercial developers and local contract manufacturing organizations are expanding to ensure consistent isotope availability. Diagnostic laboratories are diversifying supplier networks to avoid single-source dependencies, and research institutions are forming consortia to pool resources for in-house radiochemistry capabilities. Despite short-term cost pressures, these adjustments are catalyzing a shift toward a more resilient, regionally decentralized manufacturing base that can better withstand geopolitical and trade uncertainties.

Key Segmentation Insights Across Applications, Technologies, End Users

Market segmentation reveals nuanced drivers across multiple dimensions. When analyzing applications, oncology continues to dominate with targeted radioligand therapies, while cardiology, endocrinology, gastroenterology, immunology, infectious diseases, neurology and pulmonology each present unique diagnostic and therapeutic opportunities based on disease-specific biomarkers. From a technology perspective, the increasing clinical adoption of radiopharmaceuticals is complemented by growth in monoclonal antibodies, nanoparticles, peptides, fluorescent proteins and emerging biomarker platforms.

In the end-use landscape, commercial channels-spanning biotechnology and pharmaceutical companies-control drug development and regulatory filings, whereas academic and research institutions, diagnostic laboratories and hospitals drive clinical validation and point-of-care deployment. The development process also bifurcates into contractual partnerships with third-party specialists and in-house initiatives under proprietary branding, each offering distinct advantages in flexibility and control. Finally, service models differentiate between diagnostic and therapeutic services, underscoring the dual revenue streams and operational complexities inherent to integrated theranostic offerings.

Key Regional Insights in the Global Theranostics Market

Regional dynamics play a critical role in shaping market adoption. In the Americas, mature regulatory pathways and established reimbursement systems underpin robust commercial activity in both diagnostics and therapeutics. The Europe, Middle East & Africa region leverages harmonized approval processes under the European Medicines Agency, alongside growing investment in precision oncology centers in key markets like Germany, France and the United Arab Emirates. Asia-Pacific is emerging as a high-growth frontier, driven by government initiatives to bolster domestic manufacturing, rising prevalence of chronic diseases and expanding healthcare infrastructure in China, India, Japan and Australia.

Each region presents distinct opportunities: the Americas benefit from strong clinical trial networks, EMEA continues to refine cross-border collaboration frameworks, and APAC is rapidly scaling capacity to meet escalating demand for personalized interventions.

Key Companies Driving Innovation in Theranostics

Several leading organizations are pioneering theranostic innovation through targeted pipelines and strategic alliances. Actinium Pharmaceuticals, Inc. focuses on radioimmunotherapy, while Ariceum Therapeutics GmbH advances novel radiolabeled small molecules. Astellas Pharma Inc. integrates peptide-based probes into its oncology portfolio, and BAMF Health collaborates on antibody-drug conjugates. Bayer AG utilizes its diagnostic expertise to optimize companion imaging agents, whereas bioMérieux SA develops integrated biomarker platforms.

Biosynth Ltd. supplies custom peptide radiolabeling services, and Cardinal Health, Inc. enhances distribution networks for radiopharmaceuticals. Cerebral Therapeutics, Inc. and Clarity Pharmaceuticals are applying targeted isotopes to neurological disorders. Curasight A/S and Curium Inc. expand imaging agent offerings, while Evergreen Theragnostics, Inc. pioneers point-of-care radiochemistry. GE HealthCare Technologies, Inc. equips hospitals with next-generation imaging systems, complemented by Hermes Medical Solutions AB’s digital workflow tools. Icon Group and Invicro, LLC provide contract services from early-phase research to clinical trials. Indi Molecular, Inc. and Integrated Clinical Oncology Network Pty Ltd. focus on regional delivery models, and Ipsen Pharma emphasizes peptide radioligand therapies. Radiopharm Theranostics Limited and Ratio Therapeutics are driving late-stage clinical studies, supported by Siemens Healthineers AG’s integrated imaging platforms. SOFIE Co. and Telix Pharmaceuticals Limited commercialize theranostic agents globally, while United Theranostics develops in-house manufacturing solutions.

Actionable Recommendations for Industry Leaders

Industry leaders can capitalize on current momentum by pursuing several strategic initiatives. First, investing in domestic production capabilities for critical isotopes and radiolabeling reagents will buffer against trade-related disruptions. Second, forging interdisciplinary partnerships between pharmaceutical developers, diagnostic labs and academic centers can accelerate clinical validation and broaden market access. Third, implementing artificial intelligence-driven analytics for biomarker discovery and patient stratification will enhance pipeline efficiency and clinical trial success rates.

Fourth, expanding presence in high-growth Asia-Pacific markets through localized partnerships and regulatory harmonization efforts will diversify revenue streams. Fifth, engaging proactively with regulatory bodies to shape adaptive frameworks for combined diagnostics and therapeutics will reduce approval timelines. Finally, strengthening supply chain resilience by diversifying logistics providers and establishing on-demand manufacturing platforms will ensure uninterrupted delivery of critical agents.

Conclusion: Harnessing Opportunities in Theranostics

Theranostics stands at the forefront of personalized healthcare, offering unparalleled precision in diagnosing and treating complex diseases. The interplay of advanced radiopharmaceuticals, robust biomarker discovery and integrated service models has created a fertile environment for innovation. While regulatory and trade pressures present challenges, they also catalyze the development of more resilient manufacturing networks and collaborative frameworks.

By aligning strategic investments with emerging technological trends and regional market dynamics, organizations can secure competitive advantages. Proactive engagement with regulatory agencies, adaptive supply chain strategies and partnerships across the value chain will be instrumental in sustaining growth. As the therapeutic landscape evolves, the ability to deliver integrated diagnostic and therapeutic solutions will define industry leaders and shape the next generation of patient-centered care.

Market Segmentation & Coverage

This research report categorizes the Theranostics Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Cardiology
  • Endocrinology
  • Gastroenterology
  • Immunology
  • Infectious Diseases
  • Neurology
  • Oncology
  • Pulmonology
  • Biomarkers
  • Fluorescent Proteins
  • Monoclonal Antibodies
  • Nanoparticles
  • Peptides
  • Radiopharmaceuticals
  • Commercial
    • Biotechnology Companies
    • Pharmaceutical Companies
  • End Users
    • Academic & Research Institutions
    • Diagnostic Laboratories
    • Hospitals
  • Contractual
    • Third-Party Development
  • In-House
    • Own Branded
  • Type
    • Diagnostic Services
    • Therapeutic Services

This research report categorizes the Theranostics Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Theranostics Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics GmbH
  • Astellas Pharma Inc.
  • BAMF Health
  • Bayer AG
  • bioMérieux SA
  • Biosynth Ltd.
  • Cardinal Health, Inc.
  • Cerebral Therapeutics, Inc.
  • Clarity Pharmaceuticals
  • Curasight A/S
  • Curium Inc.
  • Evergreen Theragnostics, Inc.
  • GE HealthCare Technologies, Inc.
  • Hermes Medical Solutions AB
  • Icon Group
  • Indi Molecular, Inc.
  • Integrated Clinical Oncology Network Pty Ltd.
  • Invicro, LLC
  • Ipsen Pharma
  • Radiopharm Theranostics Limited
  • Ratio Therapeutics
  • Siemens Healthineers AG
  • SOFIE Co.
  • Telix Pharmaceuticals Limited
  • United Theranostics

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Theranostics Market, by Application
8.1. Introduction
8.2. Cardiology
8.3. Endocrinology
8.4. Gastroenterology
8.5. Immunology
8.6. Infectious Diseases
8.7. Neurology
8.8. Oncology
8.9. Pulmonology
9. Theranostics Market, by Technology
9.1. Introduction
9.2. Biomarkers
9.3. Fluorescent Proteins
9.4. Monoclonal Antibodies
9.5. Nanoparticles
9.6. Peptides
9.7. Radiopharmaceuticals
10. Theranostics Market, by End Use
10.1. Introduction
10.2. Commercial
10.2.1. Biotechnology Companies
10.2.2. Pharmaceutical Companies
10.3. End Users
10.3.1. Academic & Research Institutions
10.3.2. Diagnostic Laboratories
10.3.3. Hospitals
11. Theranostics Market, by Development Process
11.1. Introduction
11.2. Contractual
11.2.1. Third-Party Development
11.3. In-House
11.3.1. Own Branded
12. Theranostics Market, by Service Model
12.1. Introduction
12.2. Type
12.2.1. Diagnostic Services
12.2.2. Therapeutic Services
13. Americas Theranostics Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Theranostics Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Theranostics Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Actinium Pharmaceuticals, Inc.
16.3.2. Ariceum Therapeutics GmbH
16.3.3. Astellas Pharma Inc.
16.3.4. BAMF Health
16.3.5. Bayer AG
16.3.6. bioMérieux SA
16.3.7. Biosynth Ltd.
16.3.8. Cardinal Health, Inc.
16.3.9. Cerebral Therapeutics, Inc.
16.3.10. Clarity Pharmaceuticals
16.3.11. Curasight A/S
16.3.12. Curium Inc.
16.3.13. Evergreen Theragnostics, Inc.
16.3.14. GE HealthCare Technologies, Inc.
16.3.15. Hermes Medical Solutions AB
16.3.16. Icon Group
16.3.17. Indi Molecular, Inc.
16.3.18. Integrated Clinical Oncology Network Pty Ltd.
16.3.19. Invicro, LLC
16.3.20. Ipsen Pharma
16.3.21. Radiopharm Theranostics Limited
16.3.22. Ratio Therapeutics
16.3.23. Siemens Healthineers AG
16.3.24. SOFIE Co.
16.3.25. Telix Pharmaceuticals Limited
16.3.26. United Theranostics
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. THERANOSTICS MARKET MULTI-CURRENCY
FIGURE 2. THERANOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. THERANOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL THERANOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL THERANOSTICS MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL THERANOSTICS MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. THERANOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. THERANOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. THERANOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL THERANOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL THERANOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL THERANOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL THERANOSTICS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL THERANOSTICS MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL THERANOSTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL THERANOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL THERANOSTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL THERANOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL THERANOSTICS MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL THERANOSTICS MARKET SIZE, BY BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL THERANOSTICS MARKET SIZE, BY FLUORESCENT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL THERANOSTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL THERANOSTICS MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL THERANOSTICS MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL THERANOSTICS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL THERANOSTICS MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL THERANOSTICS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL THERANOSTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL THERANOSTICS MARKET SIZE, BY END USERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL THERANOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL THERANOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL THERANOSTICS MARKET SIZE, BY CONTRACTUAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL THERANOSTICS MARKET SIZE, BY THIRD-PARTY DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL THERANOSTICS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL THERANOSTICS MARKET SIZE, BY OWN BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL THERANOSTICS MARKET SIZE, BY TYPE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL THERANOSTICS MARKET SIZE, BY DIAGNOSTIC SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL THERANOSTICS MARKET SIZE, BY THERAPEUTIC SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 75. CANADA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. CANADA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 77. CANADA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 78. CANADA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 79. CANADA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 80. CANADA THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 81. CANADA THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 82. CANADA THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 83. CANADA THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 84. CANADA THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. MEXICO THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. MEXICO THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 88. MEXICO THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 89. MEXICO THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 92. MEXICO THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 93. MEXICO THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 94. MEXICO THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES THERANOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 126. AUSTRALIA THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 127. CHINA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 128. CHINA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 129. CHINA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 130. CHINA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 131. CHINA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 132. CHINA THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 133. CHINA THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 134. CHINA THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 135. CHINA THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 136. CHINA THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. INDIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. INDIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 139. INDIA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 140. INDIA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 141. INDIA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 142. INDIA THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 143. INDIA THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 144. INDIA THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 145. INDIA THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 146. INDIA THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. INDONESIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. INDONESIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 153. INDONESIA THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 154. INDONESIA THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 155. INDONESIA THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 156. INDONESIA THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. JAPAN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 158. JAPAN THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 159. JAPAN THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 160. JAPAN THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 161. JAPAN THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 162. JAPAN THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 163. JAPAN THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 164. JAPAN THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 165. JAPAN THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 166. JAPAN THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 167. MALAYSIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. MALAYSIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 171. MALAYSIA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 172. MALAYSIA THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 173. MALAYSIA THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 174. MALAYSIA THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 175. MALAYSIA THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 176. MALAYSIA THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. PHILIPPINES THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 178. PHILIPPINES THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 180. PHILIPPINES THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 181. PHILIPPINES THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 182. PHILIPPINES THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 183. PHILIPPINES THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 184. PHILIPPINES THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 185. PHILIPPINES THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 186. PHILIPPINES THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. SINGAPORE THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. SINGAPORE THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 189. SINGAPORE THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 190. SINGAPORE THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 191. SINGAPORE THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 192. SINGAPORE THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 193. SINGAPORE THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 194. SINGAPORE THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 195. SINGAPORE THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 196. SINGAPORE THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. SOUTH KOREA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 199. SOUTH KOREA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 200. SOUTH KOREA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 201. SOUTH KOREA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH KOREA THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH KOREA THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 204. SOUTH KOREA THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 205. SOUTH KOREA THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 206. SOUTH KOREA THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 207. TAIWAN THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. TAIWAN THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. TAIWAN THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 210. TAIWAN THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 211. TAIWAN THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 212. TAIWAN THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 213. TAIWAN THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 214. TAIWAN THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 215. TAIWAN THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 216. TAIWAN THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 217. THAILAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. THAILAND THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 219. THAILAND THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 220. THAILAND THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 221. THAILAND THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 222. THAILAND THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 223. THAILAND THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 224. THAILAND THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 225. THAILAND THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 226. THAILAND THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 227. VIETNAM THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. VIETNAM THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 229. VIETNAM THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 230. VIETNAM THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 231. VIETNAM THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 232. VIETNAM THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 233. VIETNAM THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 234. VIETNAM THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 235. VIETNAM THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 236. VIETNAM THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA THERANOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 248. DENMARK THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. DENMARK THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 250. DENMARK THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 251. DENMARK THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 252. DENMARK THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 253. DENMARK THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 254. DENMARK THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 255. DENMARK THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 256. DENMARK THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 257. DENMARK THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 258. EGYPT THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 259. EGYPT THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 260. EGYPT THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 261. EGYPT THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 262. EGYPT THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 263. EGYPT THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 264. EGYPT THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 265. EGYPT THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 266. EGYPT THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 267. EGYPT THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 268. FINLAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 269. FINLAND THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. FINLAND THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 271. FINLAND THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 272. FINLAND THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 273. FINLAND THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 274. FINLAND THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 275. FINLAND THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 276. FINLAND THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 277. FINLAND THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 278. FRANCE THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 279. FRANCE THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 280. FRANCE THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 281. FRANCE THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 282. FRANCE THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 283. FRANCE THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 284. FRANCE THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 285. FRANCE THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 286. FRANCE THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 287. FRANCE THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 288. GERMANY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 289. GERMANY THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 290. GERMANY THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 291. GERMANY THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 292. GERMANY THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 293. GERMANY THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 294. GERMANY THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 295. GERMANY THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 296. GERMANY THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 297. GERMANY THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 301. ISRAEL THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 302. ISRAEL THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 303. ISRAEL THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 304. ISRAEL THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 305. ISRAEL THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 306. ISRAEL THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 307. ISRAEL THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 308. ITALY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 309. ITALY THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 310. ITALY THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 311. ITALY THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 312. ITALY THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 313. ITALY THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 314. ITALY THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 315. ITALY THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 316. ITALY THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 317. ITALY THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 318. NETHERLANDS THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 319. NETHERLANDS THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 320. NETHERLANDS THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 321. NETHERLANDS THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 322. NETHERLANDS THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 323. NETHERLANDS THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 324. NETHERLANDS THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 325. NETHERLANDS THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 326. NETHERLANDS THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 327. NETHERLANDS THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 328. NIGERIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 329. NIGERIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 330. NIGERIA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 331. NIGERIA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 332. NIGERIA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 333. NIGERIA THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 334. NIGERIA THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 335. NIGERIA THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 336. NIGERIA THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 337. NIGERIA THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 338. NORWAY THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 339. NORWAY THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 340. NORWAY THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 341. NORWAY THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 342. NORWAY THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 343. NORWAY THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 344. NORWAY THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 345. NORWAY THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 346. NORWAY THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 347. NORWAY THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 348. POLAND THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 349. POLAND THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 350. POLAND THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 351. POLAND THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 352. POLAND THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 353. POLAND THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 354. POLAND THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 355. POLAND THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 356. POLAND THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 357. POLAND THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 358. QATAR THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 359. QATAR THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 360. QATAR THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 361. QATAR THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 362. QATAR THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 363. QATAR THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 364. QATAR THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 365. QATAR THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 366. QATAR THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 367. QATAR THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 368. RUSSIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 369. RUSSIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 370. RUSSIA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 371. RUSSIA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 372. RUSSIA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 373. RUSSIA THERANOSTICS MARKET SIZE, BY DEVELOPMENT PROCESS, 2018-2030 (USD MILLION)
TABLE 374. RUSSIA THERANOSTICS MARKET SIZE, BY CONTRACTUAL, 2018-2030 (USD MILLION)
TABLE 375. RUSSIA THERANOSTICS MARKET SIZE, BY IN-HOUSE, 2018-2030 (USD MILLION)
TABLE 376. RUSSIA THERANOSTICS MARKET SIZE, BY SERVICE MODEL, 2018-2030 (USD MILLION)
TABLE 377. RUSSIA THERANOSTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 378. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 379. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 380. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
TABLE 381. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY COMMERCIAL, 2018-2030 (USD MILLION)
TABLE 382. SAUDI ARABIA THERANOSTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 383. SA

Companies Mentioned

  • Actinium Pharmaceuticals, Inc.
  • Ariceum Therapeutics GmbH
  • Astellas Pharma Inc.
  • BAMF Health
  • Bayer AG
  • bioMérieux SA
  • Biosynth Ltd.
  • Cardinal Health, Inc.
  • Cerebral Therapeutics, Inc.
  • Clarity Pharmaceuticals
  • Curasight A/S
  • Curium Inc.
  • Evergreen Theragnostics, Inc.
  • GE HealthCare Technologies, Inc.
  • Hermes Medical Solutions AB
  • Icon Group
  • Indi Molecular, Inc.
  • Integrated Clinical Oncology Network Pty Ltd.
  • Invicro, LLC
  • Ipsen Pharma
  • Radiopharm Theranostics Limited
  • Ratio Therapeutics
  • Siemens Healthineers AG
  • SOFIE Co.
  • Telix Pharmaceuticals Limited
  • United Theranostics

Methodology

Loading
LOADING...

Related Topics

Related Reports

Radiopharmaceutical Theranostics Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Radiopharmaceutical Theranostics Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Theranostics: Global Markets 2024-2029 - Product Image

Theranostics: Global Markets 2024-2029

  • Report
  • 118 Pages
  • Global
From
Radiopharmaceutical Theranostics Market Report 2025 - Product Image

Radiopharmaceutical Theranostics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Theranostics Market Report 2025 - Product Image

Theranostics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Radiopharmaceutical Theranostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Radiopharmaceutical Theranostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 105 Pages
  • Global
From

About the Theranostics Market

Theranostics is a field of medicine that combines diagnostics and therapeutics to provide personalized treatments for patients. It is closely related to genomics, which is the study of an individual's genetic makeup. Theranostics uses genomic information to identify the best treatment for a patient, based on their unique genetic profile. This approach is becoming increasingly popular as it allows for more precise and effective treatments. Theranostics is used in a variety of medical fields, including oncology, neurology, and cardiology. It is also being used to develop new treatments for rare diseases. By combining genomic data with other medical information, such as imaging and laboratory tests, doctors can better understand a patient's condition and develop more effective treatments. Some companies in the Theranostics market include Illumina, Thermo Fisher Scientific, and Qiagen. These companies provide products and services related to genomics, such as DNA sequencing, gene expression analysis, and bioinformatics. They also offer products and services related to theranostics, such as biomarker discovery and drug development. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.